Source: Annual Congress 2009 - Treatment of airways disease
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
C. Ranasinha, A. Sudeera, J. Mangala, A. Goonathilake (Ragama, Moratuwa, Gangodawila, Sri Lanka). Drug deposition by cascade impactor of two dry powder inhalers. Eur Respir J 2009; 34: Suppl. 53, 2086

Member's Comments

No comment yet.

Related content which might interest you: In-use performance of sofotec´s dry powder inhaler Source: Eur Respir J 2004; 24: Suppl. 48, 584s Year: 2004 The genuair® inhaler: a novel multidose dry powder inhaler for the delivery of various types of inhalation powder Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009 Development of a powder for inhalation with R,R-Glycopyrrolate as active ingredient for the delivery from a novel multidose dry powder inhaler Source: Eur Respir J 2003; 22: Suppl. 45, 471s Year: 2003 Use of dry powder inhalers in COPD Source: Eur Respir J 2005; 26: Suppl. 49, 286s Year: 2005 Clinical equivalence of budesonide delivered via two dry powder inhalers Source: Eur Respir J 2005; 26: Suppl. 49, 339s Year: 2005 Equivalence testing of salbutamol dry powder inhalers by in vitro impaction Source: Eur Respir J 2001; 18: Suppl. 33, 100s Year: 2001 Inhalation parameters from an integrated electronic multidose dry powder inhaler (eMDPI) Source: International Congress 2018 – Asthma: clinical screening tools Year: 2018 Reliability of inhalation therapy through a multidose dry powder inhaler Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007 Efficacy and safety of salbutamol delivered via a novel multidose dry powder inhaler in comparison with two conventional dry powder inhalers and a pMDI in asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 50s Year: 2001 Do dry powder inhalers (DPIs) have a ‘Goldilocks Zone’ of inhalation? In vitro lung deposition of Budesonide/Formoterol (BUD/FORM) DPI with different inhalation profiles Source: International Congress 2017 – Pulmonary drug and devices delivery Year: 2017 Applicability of dry powder inhalers in children with CF Source: International Congress 2016 – Cystic fibrosis: inflammation, microbiology, management and monitoring Year: 2016 Consider the turbulent energy not inhalation flow when patients use dry powder inhalers (DPIs) Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs Year: 2012 Innovative and precise aerodynamic concept of a multidose dry powder inhaler (MDPI) Source: Eur Respir J 2004; 24: Suppl. 48, 166s Year: 2004 A study to evaluate the therapeutic equivalence of a new multidose budesonide dry powder inhaler with a conventional budesonide dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001 Comparison of the release characteristics of formoterol dihydrate powder for inhalation delivered through two different types of multidose dry powder inhalers (MDPI) Source: Eur Respir J 2005; 26: Suppl. 49, 126s Year: 2005 Flow-dependent performance of several formoterol dry powder inhalers (DPIs) Source: Eur Respir J 2006; 28: Suppl. 50, 435s Year: 2006 Dose proportionality of in vitro fine particle dose for dry powder inhaler combination products Source: Eur Respir J 2002; 20: Suppl. 38, 541s Year: 2002 In vitro testing of two budesonide dry powder inhalers at different flow rates Source: Eur Respir J 2001; 18: Suppl. 33, 101s Year: 2001 Pharmaceutical performances of formoterol delivered from a novel multidose dry powder inhaler Source: Eur Respir J 2001; 18: Suppl. 33, 134s Year: 2001 Ex-vivo emitted dose characteristics for combination formulations in dry powder inhalers (DPI) Source: Eur Respir J 2003; 22: Suppl. 45, 472s Year: 2003